IP Library Granted Patent US 7,595,346
Granted Patent B2
US 7,595,346 · App. 12/030,691 · Granted Sep 29, 2009

Curcumin analogues and uses thereof

Assignees: The University of North Carolina at Chapel Hill; The University of Rochester Medical Center; Androscience Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,595,346
App. No.
12/030,691
Granted
Sep 29, 2009
Kind
B2
Abstract

The present invention relates to compounds capable of acting as androgen receptor antagonists, pharmaceutical formulations containing the same, and methods of use thereof. Such uses include, but are not limited to, use as antitumor agents, particularly for the treatment of cancers such as colon, skin and prostate cancer and to induce androgen receptor antagonist activity in a subject afflicted with an androgen-related affliction. Examples of androgen-related afflictions include, but are not limited to, baldness, hirsutism, behavioral disorders, acne, and uninhibited spermatogenesis wherein inhibition of spermatogenesis is so desired.

Claims (18)

1. A compound having the following structure:

or a pharmaceutical acceptable salt thereof.

2. A pharmaceutical formulation comprising a compound of

or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier.

3. A method of treating an androgen related cancer, comprising administering to a subject in need thereof a treatment effective amount of a compound having the structure

or a pharmaceutically acceptable salt thereof, wherein said androgen related cancer is selected from the group consisting of skin cancer, small cell lung cancer, esophageal cancer, colon cancer, breast cancer, endometrial cancer, ovarian cancer and prostate cancer.

4. A method of inducing androgen receptor antagonist activity, said method comprising contacting a cell with an androgen receptor antagonist effective amount of a compound having the structure

or a pharmaceutically acceptable salt thereof.

5. A method of inducing androgen receptor antagonist activity in a subject afflicted with an androgen-related affliction, said method comprising administering an androgen receptor antagonist effective amount of a compound having the structure

or a pharmaceutically acceptable salt thereof, wherein said androgen-related affliction is selected from the group consisting of hirsutism, acne and baldness.

6. The method according to claim 3 , wherein said cancer is prostate cancer.

7. The method according to claim 3 , wherein said cancer is colon cancer.

8. The method according to claim 4 , wherein said cell is a cancer cell.

9. The method according to claim 4 , wherein said contacting step is carried out in vivo.

10. The method according to claim 4 , wherein said contacting step is carried out in vitro.

11. The method according to claim 5 , wherein said subject is afflicted with baldness.

12. The method according to claim 5 , wherein said subject is afflicted with hirsutism.

13. The method according to claim 5 , wherein said subject is afflicted with acne.

Assignments (2)
CONFIRMATORY LICENSE Recorded Feb 8, 2018
From: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
To: NIH-DEITR
Reel/Frame 045282/0905 →
EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE Recorded Jan 9, 2009
From: UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 022081/0163 →
Continuity (2)
Continuation 1096672300 · Oct 15, 2004
Related Publication 20080146660A1 · Jun 19, 2008